Cebix Inc., of La Jolla, Calif., closed a $30.9 million Series B investment to support development of its investigational drug for peripheral neuropathy, Ersatta. It also reported new results from a Phase I/II trial showing the drug had efficacy in patients with Type I diabetes dosed once weekly for 12 weeks.